GBS Inc. (GBS)
Price:
0.47 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Abiomed, Inc.
VALUE SCORE:
0
2nd position
Insulet Corporation
VALUE SCORE:
9
The best
Viemed Healthcare, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
NEWS
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
globenewswire.com
2025-05-19 16:05:00First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
globenewswire.com
2025-05-09 17:00:00First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient Populations
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
globenewswire.com
2025-04-08 16:05:00Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
globenewswire.com
2025-04-03 18:18:00Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
prnewswire.com
2024-12-17 17:16:00LUND, Sweden , Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS. Data from the 15-HMedIdeS-09 study demonstrated that severe GBS patients treated with a single dose of imlifidase (0.25 mg/kg) plus intravenous immunoglobulin (IVIg) had rapid overall improvement in functional status including expedited recovery of muscle strength, fast return to independently walking, and a median time to independently walk (e.g.
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
globenewswire.com
2024-12-16 07:30:00Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif.
GBS, Inc. (GBS) Q4 2022 Earnings Call Transcript
seekingalpha.com
2022-09-01 18:40:27GBS, Inc. (NASDAQ:GBS ) Q4 2022 Earnings Conference Call August 31, 2022 4:30 PM ET Company Participants Steven Boyages - Chairman and Interim CEO Spiro Sakiris - CFO Conference Call Participants John Vandermosten - Zacks SCR Operator Greetings, and thank you for joining us for GBS, Inc's Fourth Quarter and Fiscal Yearend 2022 Financial and Business Update Conference Call. Currently all participants are in a listen-only mode.
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31
globenewswire.com
2022-08-29 09:05:00Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
GBS Inc. to Present at the H.C. Wainwright Global Investment Conference
globenewswire.com
2022-05-16 16:05:00NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings. Please see additional details below:
GBS Inc.'s (GBS) CEO Dr. Steven Boyages on Q3 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-05-14 23:28:18GBS Inc. (NASDAQ:GBS ) Q3 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Dr. Steven Boyages - Chairman and Interim CEO Spiro Sakiris - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the GBS Inc. Third Quarter 2022 Earnings Conference Call.
GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10
globenewswire.com
2022-05-03 09:05:00Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
4 Trending Penny Stocks to Add to Your Watchlist Right Now
pennystocks.com
2022-03-21 16:37:51Are these trending penny stocks on your watchlist right now? The post 4 Trending Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GBS Inc. to Participate in the Upcoming March Investor Conferences
globenewswire.com
2022-03-07 08:30:00NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in March and invites investors to participate in one-on-one meetings. Please see additional details below:
GBS Inc. (GBS) CEO Steven Boyages on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-02-10 21:15:20GBS Inc. (GBS) CEO Steven Boyages on Q2 2022 Results - Earnings Call Transcript
GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10
globenewswire.com
2022-02-07 08:30:00Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences
globenewswire.com
2021-12-20 07:10:00NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below:
No data to display
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
globenewswire.com
2025-05-19 16:05:00First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
globenewswire.com
2025-05-09 17:00:00First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient Populations
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
globenewswire.com
2025-04-08 16:05:00Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
globenewswire.com
2025-04-03 18:18:00Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
prnewswire.com
2024-12-17 17:16:00LUND, Sweden , Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS. Data from the 15-HMedIdeS-09 study demonstrated that severe GBS patients treated with a single dose of imlifidase (0.25 mg/kg) plus intravenous immunoglobulin (IVIg) had rapid overall improvement in functional status including expedited recovery of muscle strength, fast return to independently walking, and a median time to independently walk (e.g.
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
globenewswire.com
2024-12-16 07:30:00Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif.
GBS, Inc. (GBS) Q4 2022 Earnings Call Transcript
seekingalpha.com
2022-09-01 18:40:27GBS, Inc. (NASDAQ:GBS ) Q4 2022 Earnings Conference Call August 31, 2022 4:30 PM ET Company Participants Steven Boyages - Chairman and Interim CEO Spiro Sakiris - CFO Conference Call Participants John Vandermosten - Zacks SCR Operator Greetings, and thank you for joining us for GBS, Inc's Fourth Quarter and Fiscal Yearend 2022 Financial and Business Update Conference Call. Currently all participants are in a listen-only mode.
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31
globenewswire.com
2022-08-29 09:05:00Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
GBS Inc. to Present at the H.C. Wainwright Global Investment Conference
globenewswire.com
2022-05-16 16:05:00NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings. Please see additional details below:
GBS Inc.'s (GBS) CEO Dr. Steven Boyages on Q3 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-05-14 23:28:18GBS Inc. (NASDAQ:GBS ) Q3 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Dr. Steven Boyages - Chairman and Interim CEO Spiro Sakiris - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the GBS Inc. Third Quarter 2022 Earnings Conference Call.
GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10
globenewswire.com
2022-05-03 09:05:00Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
4 Trending Penny Stocks to Add to Your Watchlist Right Now
pennystocks.com
2022-03-21 16:37:51Are these trending penny stocks on your watchlist right now? The post 4 Trending Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GBS Inc. to Participate in the Upcoming March Investor Conferences
globenewswire.com
2022-03-07 08:30:00NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in March and invites investors to participate in one-on-one meetings. Please see additional details below:
GBS Inc. (GBS) CEO Steven Boyages on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-02-10 21:15:20GBS Inc. (GBS) CEO Steven Boyages on Q2 2022 Results - Earnings Call Transcript
GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10
globenewswire.com
2022-02-07 08:30:00Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences
globenewswire.com
2021-12-20 07:10:00NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below: